# A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

> **NCT03969134** · PHASE2 · COMPLETED · sponsor: **University of York** · enrollment: 86 (actual)

## Conditions studied

- Leishmaniasis, Cutaneous

## Interventions

- **BIOLOGICAL:** ChAd63-KH
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03969134
- **Lead sponsor:** University of York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-06
- **Primary completion:** 2022-08-31
- **Final completion:** 2023-02-28
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969134, "A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03969134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*